|
|
The Impact of Nanotechnology in Drug DiscoveryPublished by: Drug and Market Development Publishing Published: Apr. 1, 2005 - 218 Pages Table of ContentsExecutive Summary E.1 Introduction E.2 Drivers, Restraints and Challenges Affecting the Growth of Nano-Enabled Drug Discovery. E.3 The Pharmaceutical Market, Regulatory Factors and Sources of Funding for Nanotechnology E.4 Which Countries will Lead in Nano-Enabled Drug Discovery? E.5 Nano-enabled Drug Discovery Technologies and Products E.6 The Players E.7 Market Forecast Summaries Chapter One Introduction 1.1 Overview 1.2 Objectives 1.3 Scope of the Report⎯Research Methodology and Information Sources 1.4 Plan of Report Chapter Two Drivers, Restraints, Challenges, Regulatory Issues and Government Funding Policies 2.1 Introduction 2.2 Drivers for the Growth of Nano-enabled Drug Discovery 2.2.1 Social and economic drivers 2.2.2 Technological Drivers 2.2.3 Increased Funding Drives Nano-enabled Drug Discovery 2.3 Factors Restricting the Market Growth of Nano-enabled Drug Discovery 2.3.1 Uncertainty 2.3.2 Public Awareness and Perception 2.3.3 Environmental Concerns 2.3.4 Detection of Incurable Diseases Could Place Immense Pressure on Pharmaceutical Companies 2.3.5 Huge Expectations May Not Be Realized 2.4 Technology Challenges 2.4.1 Nanotechnologies are Required to Meet the Demands for Drug- Discovery Applications 2.4.2 The Long-Term Stability of Nanomaterials Causes Concern 2.4.3 Technical Issues In Nano-Assembly and Molecular Manufacturing are Affecting Rapid Commercialization 2.4.4 Overcoming Barriers to Collaboration 2.4.5 Lack of Test Standardization 2.4.6 Scalability Posing a Challenge to Nanomedicine Initiatives. 2.4.7 Pharmaceutical Companies May Be Reluctant to Invest In Nanotechnology 2.5 The Pharmaceutical Market, Regulatory Factors and Sources of Funding for Nanotechnology 2.5.1 United States 2.5.2 Canada 2.5.3 Europe 2.5.3.1 Belgium and the Netherlands 2.5.3.2 Denmark 2.5.3.3 Finland 2.5.3.4 Sweden 2.5.3.5 France 2.5.3.6 Germany 2.5.3.7 United Kingdom. 2.5.3.8 Ireland 2.5.3.9 Switzerland 2.5.3.10 Italy 2.5.4 Japan 2.5.5 Taiwan 2.5.6 Singapore 2.5.7 South Korea 2.5.8 China 2.5.9 Australia. 2.5.10 Israel Chapter Three Applications of Nanotechnology in Drug Discovery 3.1 A Historical Overview of the Drug Discovery Process 3.2 An Introduction to Nanotechnology in Drug Discovery and Development 3.3 Nano-enabled Drug Discovery Tools 3.3.1 Atomic Force Microscopy (AFM) and the Congruent Force Intermolecular Test. 3.3.2 Field-Ion Microscope 3.3.3 Near-field Scanning Optical Microscope (SNOM or NSOM) 3.3.4 Surface Plasmon Resonance. 3.3.5 Nano-Mass Spectroscopy 3.3.6 Dip-Pen Nanolithography (DPN) 3.4 Microarrays and Nanoarrays 3.5 Microfluidics and Nanofluidics 3.6 Nanoparticles for Drug Discovery 3.6.1 Quantum Dots (QDots) and Gold Nanoparticles for High-Content and Initial Drug Screening 3.6.2 Nanoshells for Raman Spectroscopy 3.6.3 Nanobarcode Particles. 3.7 Nanomaterial Drugs 3.7.1 Abraxane 3.7.2 RenaZorb 3.7.3 Antimicrobial Emulsions 3.7.4 Antioxidant and Anti-HIV Fullerenes 3.8 Future Developments Chapter Four The Players 4.1 Introduction 4.2 3DM (PuraMatrix) 4.3 Aclara BioSciences 4.4 Advion BioSciences 4.5 Agilent Technologies 4.6 Alnis BioSciences 4.7 American Pharmaceutical Partners (Abraxis Oncology) 4.8 BioCrystal 4.9 BioForce Nanosciences 4.10 BioTrove 4.11 Caliper Life Sciences 4.12 Cepheid 4.13 CombiMatrix 4.14 CrystalPlex 4.15 C Sixty 4.16 Eksigent Technologies 4.17 Evident Technologies 4.18 Fluidigm 4.19 GeneFluidics 4.20 Gyros 4.21 NanoBio 4.22 Nanogen 4.23 NanoHorizons 4.24 Nanosphere 4.25 Nanostream 4.26 PharmaSeq 4.27 Protiveris 4.28 Quantum Dot Corp. 4.29 Sequenom 4.30 Zyomyx Chapter Five Eight-Year Projections of Nano-enabled Drug Discovery Revenues. 5.1 A Justification for Forecasting 5.2 Forecasting Goals and Methodology 5.2.1 Size of Addressable Markets 5.3 Forecast of Nano-enabled Drug Discovery Revenues 5.3.1 Forecast of Lab-on-Chip/Array-Based Nano-enabled Drug Discovery Revenues 5.3.1.1 Competitive Structure 5.3.2 Forecast of Nanoparticle-Based Nano-enabled Drug Discovery 5.3.2.1 Competitive Structure 5.3.3 Forecast of Self-Assembly Nano-enabled Drug Discovery 5.3.3.1 Competitive Structure Acronyms and Abbreviations Used in this Report About the Author AbstractThis report discusses how nano-enabled discovery and validation technologies can expand the hit rate for promising compounds in the pipeline, and expedite their progress through to market. It covers labs-on-a-chip/arrays, as well as nanoparticulate and self-assembled solutions and provides an in-depth analysis of all the drivers, restraints, challenges, regulatory issues and government funding policies that impact nano-enabled drug discovery. Also provided are profiles of the regulatory and funding environments for this kind of technology in 20 major countries. The Report provides eight-year forecasts that break out the market by key applications segments and product types. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||